Advertisement

The evolution of European guidelines: Changing the management of cholesterol levels

  • Leif R. Erhardt
    Correspondence
    Corresponding author. Tel.: +46 40 331941; fax: +46 40 337329.
    Affiliations
    Department of Cardiology, Cardiology Research Unit, University of Lund, Malmö University Hospital, SE-205 02 Malmö, Sweden
    Search for articles by this author
  • Author Footnotes
    1 Tel.: +1 212 746 0194; fax: +1 212 746 8200.
    A. Gotto Jr.
    Footnotes
    1 Tel.: +1 212 746 0194; fax: +1 212 746 8200.
    Affiliations
    Weill Medical College of Cornell University, Olin Hall, Room 205, 445 East 69th Street, New York, NY 10021, USA
    Search for articles by this author
  • Author Footnotes
    1 Tel.: +1 212 746 0194; fax: +1 212 746 8200.

      Abstract

      Cardiovascular disease (CVD) is the leading cause of death in Europe and the US. This paper reviews the evolution of the Joint European Societies’ guidelines with respect to their lipid recommendations. We stress the importance of lowering lipid levels to, or below, the currently recommended goals and argue that patients’ global risk for CVD, rather than baseline lipid levels, should direct the intensity of lipid-lowering treatment. However, the emphasis on near-term (i.e., in the next 10 years) global risk estimation may under-emphasize the importance of considering lifetime cardiovascular risk in treatment decisions. Although various guidelines’ thresholds for treatment initiation and recommended goals differ, they are similar in the theme of treating global risk. Most clinical trials have not identified a threshold of cholesterol level beyond which lowering cholesterol levels no longer provides cardiovascular benefit. An urgent call for action is needed to improve goal attainment in patients with or at risk for CVD. Improving access to risk-reducing treatments should be a priority.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • American Heart Association
        Heart disease and stroke statistics—2003 update.
        American Heart Association, Dallas, TX2002
        • Rayner M.
        • Peterson S.
        • for the British Heart Foundation Health Promotion Research Group
        European cardiovascular disease statistics 2000 edition.
        British Heart Foundation Health Promotion Research Group, Department of Public Health, University of Oxford, Institute of Health Sciences, Oxford2000
        • De Backer G.
        • Ambrosioni E.
        • Borch-Johnsen K.
        • et al.
        European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.
        Eur Heart J. 2003; 24: 1601-1610
        • Guidelines Committee
        European Society of Hypertension—European Society of Cardiology guidelines for the management of arterial hypertension.
        J Hypertens. 2003; 21: 1011-1053
        • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
        Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
        JAMA. 2001; 285: 2486-2497
        • Grundy S.M.
        • Cleeman J.I.
        • Merz C.N.
        • et al.
        Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
        Circulation. 2004; 110: 227-239
      1. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program. JNC 7 Express: the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health; 2003.

        • Pyörälä K.
        • De Backer G.
        • Graham I.
        • Poole-Wilson P.
        • Wood D.
        Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.
        Eur Heart J. 1994; 15: 1300-1331
        • The Scandinavian Simvastatin Survival Study Group
        Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1995; 345: 1274-1275
        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • et al.
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
        N Engl J Med. 1996; 335: 1001-1009
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • et al.
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
        N Engl J Med. 1995; 333: 1301-1307
        • Second Joint Task Force of European and Other Societies on Coronary Prevention
        Prevention of coronary heart disease in clinical practice.
        Eur Heart J. 1998; 19: 1434-1503
        • Hebert P.R.
        • Gaziano J.M.
        • Chan K.S.
        • Hennekens C.H.
        Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.
        JAMA. 1997; 278: 313-321
        • Law M.R.
        • Wald N.J.
        • Rudnicka A.R.
        Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.
        BMJ. 2003; 326: 1423
        • Heart Protection Study Collaborative Group
        MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
        Lancet. 2002; 360: 7-22
        • Sever P.S.
        • Dahlof B.
        • Poulter N.R.
        • et al.
        Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
        Lancet. 2003; 361: 1149-1158
        • Conroy R.M.
        • Pyorala K.
        • Fitzgerald A.P.
        • et al.
        Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.
        Eur Heart J. 2003; 24: 987-1003
        • Anderson K.M.
        • Wilson P.W.
        • Odell P.M.
        • Kannel W.B.
        An updated coronary risk profile. A statement for health professionals.
        Circulation. 1991; 83: 356-362
        • Menotti A.
        • Puddu P.E.
        • Lanti M.
        Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study.
        Eur Heart J. 2000; 21: 365-370
        • Bhopal R.
        • Fischbacher C.
        • Vartiainen E.
        • et al.
        Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data.
        J Public Health (Oxf). 2005; 27: 93-100
        • Aktas M.K.
        • Ozduran V.
        • Pothier C.E.
        • Lang R.
        • Lauer M.S.
        Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program.
        JAMA. 2004; 292: 1462-1468
        • Law M.R.
        • Wald N.J.
        Risk factor thresholds: their existence under scrutiny.
        BMJ. 2002; 324: 1570-1576
        • EUROASPIRE Study Group
        EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events.
        Eur Heart J. 1997; 18: 1569-1582
        • EUROASPIRE Study Group
        Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.
        Eur Heart J. 2001; 22: 554-572
        • Tonstad S.
        • Rosvold E.O.
        • Furu K.
        • Skurtveit S.
        Undertreatment and overtreatment with statins: the Oslo Health Study 2000–2001.
        J Intern Med. 2004; 255: 494-502
        • Yusuf S.
        • Hawken S.
        • Ounpuu S.
        • et al.
        Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study.
        Lancet. 2004; 364: 937-952
        • Emberson J.R.
        • Whincup P.H.
        • Morris R.W.
        • Walker M.
        Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias.
        Eur Heart J. 2003; 24: 1719-1726
        • Backlund L.
        • Bring J.
        • Strender J.-E.
        GPs and students underestimate coronary risk in hypercholesterolemic patients.
        Primary Health Care Res Dev. 2004; 5: 153-161
        • Pearson T.A.
        • Laurora I.
        • Chu H.
        • Kafonek S.
        The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.
        Arch Intern Med. 2000; 160: 459-467
        • Cozma L.S.
        • Ogunko A.
        • Rees A.
        Secondary prevention of hypercholesterolaemia: results of an audit conducted in South Wales.
        Heart. 2000; 84: E3
        • Newman C.B.
        • Palmer G.
        • Silbershatz H.
        • Szarek M.
        Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients.
        Am J Cardiol. 2003; 92: 670-676
        • Pfeffer M.A.
        • Keech A.
        • Sacks F.M.
        • et al.
        Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project.
        Circulation. 2002; 105: 2341-2346
        • de Denus S.
        • Spinler S.A.
        • Miller K.
        • Peterson A.M.
        Statins and liver toxicity: a meta-analysis.
        Pharmacotherapy. 2004; 24: 584-591
        • Downs J.R.
        • Clearfield M.
        • Weis S.
        • et al.
        Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
        JAMA. 1998; 279: 1615-1622
        • Colhoun H.M.
        • Betteridge D.J.
        • Durrington P.N.
        • et al.
        Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
        Lancet. 2004; 364: 685-696
        • Cannon C.P.
        • Braunwald E.
        • McCabe C.H.
        • et al.
        Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
        N Engl J Med. 2004; 350: 1495-1504
        • Nissen S.E.
        • Tuzcu E.M.
        • Schoenhagen P.
        • et al.
        Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
        JAMA. 2004; 291: 1071-1080
        • LaRosa J.C.
        • Grundy S.M.
        • Waters D.D.
        • et al.
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N Engl J Med. 2005; 352: 1425-1435
        • Koh K.K.
        • Quon M.J.
        • Han S.H.
        • et al.
        Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
        J Am Colloid Cardiol. 2005; 45: 1649-1653
        • Bennett S.
        • Sager P.
        • Lipka L.
        • et al.
        Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
        J Womens Health (Larchmt). 2004; 13: 1101-1107
        • Wanner C.
        • Krane V.
        • Marz W.
        • et al.
        Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
        N Engl J Med. 2005; 353: 238-248
        • Pedersen T.R.
        • Faergeman O.
        • Holme I.
        • et al.
        Effect of greater LDL-C reductions on prognosis—the Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL) trial.
        Atherosclerosis. 1999; 144: 38
        • MacMahon M.
        • Kirkpatrick C.
        • Cummings C.E.
        • et al.
        A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH).
        Nutr Metab Cardiovasc Dis. 2000; 10: 195-203
      2. ACCORD, http://www.clinicaltrials.gov/ct/show/NCT00000620?order=33.

        • Gmerek A.
        • McLain R.
        • Nawrocki J.
        A 4-year placebo-controlled study of atorvastatin as prevention of CHD endpoints in patients with non-insulin dependent diabetes mellitus.
        Diabetes. 1997; 46: 363A
        • KOS Pharmaceuticals Inc.
        News release: KOS Pharmaceuticals announces commencement of landmark long-term coronary heart disease outcomes study.
        2005
      3. TROPIC, http://www.clinicaltrials.gov/ct/show/NCT00071266?order=1.

        • Fellstrom B.C.
        • Holdaas H.
        • Jardine A.G.
        Why do we need a statin trial in hemodialysis patients?.
        Kidney Int Suppl. 2003; 84: S204-S206
        • Amarenco P.
        • Bogousslavsky J.
        • Callahan A.
        • et al.
        Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
        Cerebrovasc Dis. 2003; 16: 389-395
        • Lloyd-Jones D.M.
        • Wilson P.W.
        • Larson M.G.
        • et al.
        Lifetime risk of coronary heart disease by cholesterol levels at selected ages.
        Arch Intern Med. 2003; 163: 1966-1972
        • Ulrich S.
        • Hingorani A.D.
        • Martin J.
        • Vallance P.
        What is the optimal age for starting lipid lowering treatment? A mathematical model.
        BMJ. 2000; 320: 1134-1140
        • Ridker P.M.
        • Rifai N.
        • Cook N.R.
        • Bradwin G.
        • Buring J.E.
        Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.
        JAMA. 2005; 294: 326-333
        • Albert M.A.
        • Danielson E.
        • Rifai N.
        • Ridker P.M.
        Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
        JAMA. 2001; 286: 64-70
        • Hognestad A.
        • Endresen K.
        • Wergeland R.
        • et al.
        Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients.
        J Am Colloid Cardiol. 2003; 42: 477-482
        • Nissen S.E.
        • Tuzcu E.M.
        • Schoenhagen P.
        • et al.
        Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
        N Engl J Med. 2005; 352: 29-38
        • Ridker P.M.
        • Cannon C.P.
        • Morrow D.
        • et al.
        C-reactive protein levels and outcomes after statin therapy.
        N Engl J Med. 2005; 352: 20-28
        • Erhardt L.R.
        • Pearson T.A.
        • Bruckert E.
        • et al.
        Guidelines and their implementation: a discussion document focused on the best approaches to drive implementation.
        Vasc Dis Prev. 2004; 1: 167-174
        • Hobbs F.D.
        • Erhardt L.
        Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey.
        Fam Pract. 2002; 19: 596-604
      4. European Society for Cardiology. HeartScore: the new interactive tool for predicting and managing the risk of heart attack and stroke in Europe, http://www.escardio.org/initiatives/prevention/HeartScore.htm.